SCHEMBL4798776

SCHEMBL4798776

Clc1cccc(CSc2nsc(Cl)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 4/20 0.49
CTSB P07858 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 2/20 0.48
ALOX15 P16050 1/20 0.48
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
LMNA P02545 2/20 0.45
USP2 O75604 1/20 0.45
MAPT P10636 4/20 0.45
IDO1 P14902 1/20 0.44
GSK3B P49841 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TP53 P04637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4795272 0.84 MAPT (0.42) TOP2ACTSBSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL4797641 0.84 RAB9A (0.66) CTSBSMN1; SMN2L3MBTL1ALDH1A1HPGD
SCHEMBL4797056 0.82 KDM4E (0.49) TOP2ASMN1; SMN2ALDH1A1RAB9AALOX15
SCHEMBL4798493 0.81 L3MBTL1 (0.59) CTSBSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL4797136 0.80 MAPT (0.49) SMN1; SMN2L3MBTL1ALDH1A1RAB9AALOX15
SCHEMBL4797109 0.75 RAB9A (0.51) SMN1; SMN2L3MBTL1ALDH1A1HPGDRAB9A
SCHEMBL12766911 0.75 TOP2A (0.57) TOP2ACTSBSMN1; SMN2L3MBTL1ALDH1A1
Acetic Acid SCHEMBL27339379 0.73 RAB9A (0.52) CTSBSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL4798511 0.72 KMT2A (0.58) TOP2ACTSBSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL490003 0.72 MEN1 (0.59) TOP2ACTSBSMN1; SMN2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-20060014962-A1 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-01-19 US disclosed
EP-1550661-A1 THIADIAZOLE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014962-A1 Thiadiazole compound and use thereof CBR3, TH, CYP2E1 TOP2A 4527/4885CTSB 3183/4885SMN1; SMN2 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.